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Specific paroxysmal disorders, namely benign 
infantile epilepsy (BFIE), kinesigenic dyskinesia (PKD), 
infantile convulsions and choreoathetosis (ICCA) and 
hemiplegic migraine (HM), are associated with mutations 
in the gene encoding for PRoline-Rich Transmembrane 
protein 2 (PRRT2; Figure 1A, 1B). PRRT2 is a neuron-
specific protein expressed on neuronal membranes and 
at synapses, with a prevalent presynaptic location [1, 2]. 
Several nonsense, missense and frame-shift mutations 
were identified in the PRRT2 gene, but the vast majority of 
patients (80%) carry the same frameshift single-nucleotide 
duplication (c.649dupC) that leads to a premature stop 
codon and results in a loss-of-function pathogenetic 
mechanism [3]. Despite the extensive characterization 
of PRRT2 mutations, no clear evidence for genotype-
phenotype correlation exists and the three main diseases 
(BFIE, PKD and PKD/ICCA) form a continuous spectrum, 
starting from BFIE in the first months of life and evolving 
to PKD or PKD/ICCA often in association with HM 
during adolescence [4-5]. 
To model the disorders and investigate the 
underlying neurobiological alterations, we recently 
characterized a PRRT2 knock out mouse (PRRT2 KO; 
Figure 1C), carrying a constitutive inactivation of the 
PRRT2 gene [6]. The promoterless lacZ gene integrated 
into the PRRT2 locus allowed mapping the PRRT2 
regional expression, that is not widespread, but rather 
concentrated at restricted brain areas. Interestingly, the 
expression is high in neurons of the lower hindbrain 
particularly in the cerebellum, a brain area involved 
in the generation of motor/epileptic phenotype and in 
which altered synaptic plasticity at the parallel fibers-
Purkinje cells synapse was found [6] (Figure 1D). A 
selective staining was also identified in the cerebral 
cortex, claustrum and dorsal horns of the spinal cord. 
Moreover, in the hippocampus, PRRT2 is particularly 
expressed in the hilus of the dentate gyrus, where mossy 
cells control the excitability of granule cells, playing a role 
in preventing hippocampal seizures (Figure 1D). Notably, 
all the brain regions positive for PRRT2 are involved in 
processing sensory information, motor disorders and 
epilepsy, all neurological traits present in patients with 
PRRT2 mutations. 
The PRRT2 KO mouse recapitulates many of the 
phenotypic features of the human PRRT2-linked disorders, 
showing abnormal motor behaviors and a motor/epileptic 
phenotype in response to environmental stimuli [6]. The 
motor problems are represented by gait abnormalities and 
a peculiar paroxysmal backwalking appearing early in the 
postnatal life and persisting in the adult [4]. The motor/
epileptic phenotype of PRRT2 KO mice becomes dramatic 
in response to audiogenic stimuli (Figure 1E), which 
trigger wild running, backwalking and jumping, and to the 
administration of convulsants, such as pentylentetrazole 
(Figure 1F). In both kinds of provocations, however, the 
seizure propensity was not very severe, consistent with 
the mild epileptic phenotype of patients bearing PRRT2 
mutations [4, 5]. 
Overall, the PRRT2 KO mouse reproduces the 
paroxysmal traits described in PRRT2 patients and 
characterized by sudden and short attacks that usually 
occur periodically in response to a sensory trigger. The 
episodic nature of these events suggests that they result 
from network instability caused by changes in the 
excitation/inhibition balance. Interestingly, data obtained 
in primary neurons showed that PRRT2 silencing is 
associated with alterations of synaptic transmission and 
short-term plasticity [1]. PRRT2 silencing gives rise to a 
decreased number of excitatory synapses and a marked 
impairment of fast synchronous neurotransmitter release. 
These effects are associated with a decrease in Ca2+ 
sensitivity and release probability, revealing a role for 
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Figure 1: Schematics of PRRT2 domain and 
3D structure. A., B. Regional expression in the brain 
(β-galactosidase staining; C., D.) and paroxysmal phenotype 
of the PRRT2 KO mouse in response to audiogenic E., or 
convulsive F., stimuli.
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PRRT2 at synaptic level, both during development and 
in mature synapses. The decrease in release probability is 
the basis for the highly enhanced facilitation in response 
to repeated high-frequency stimuli. Such a change was 
also observed at the parallel fiber-Purkinje cell synapses 
in the cerebellum of PRRT2 KO mice [6]. It is known that 
network dynamics, excitability and bursting behavior are 
highly dependent on the short-term plasticity dynamics of 
excitatory synapses, rather than on their basal transmission 
properties, and that enhanced facilitation promotes the 
propagation of bursting over random spiking events. 
These observations suggest indicate that the absence of 
PRRT2, through short-term plasticity changes, impairs 
the functional stability of neuronal networks, rendering 
them more susceptible to paroxysmal events triggered by 
external stimuli. Indeed, paroxysmal dyskinesia patients 
appear normal between attacks suggesting that, in the 
absence of specific triggers, homeostatic mechanisms can 
keep excitability under control. 
PRRT2 action at synaptic level is also confirmed by 
its interaction with several synaptic proteins. The analysis 
of its exact topology revealed that is a type-2 single-pass 
membrane protein with a large cytoplasmic N-terminus, 
a topology similar to the SNARE proteins syntaxin or 
VAMP/synaptobrevin [7] (Figure 1A, 1B). Indeed, PRRT2 
interacts with SNAP-25 and VAMP/synaptobrevin, two 
components of the SNARE complex responsible for 
neurotransmitter release, and with the fast Ca2+ sensors 
synaptotagmins (Syts) 1/2. The absence of PRRT2 may 
cause an uncoupling between the Ca2+ sensors and the 
SNARE complex, providing a molecular basis for the 
knockdown/knockout phenotype in synaptic transmission 
and short-term plasticity [1, 6]. These findings suggest that 
the pathogenetic mechanisms at the basis of paroxysmal 
disorders may reside in defects of synaptic function. 
Interestingly, mutations in the PNKD gene were identified 
in paroxysmal non-kinesigenic dyskinesia, a movement 
disorder similar to PKD. PNKD is expressed at the 
synapse and interacts with Rim, a synaptic protein pivotal 
for synaptic vesicle exocytosis that binds and regulates 
various types of voltage-gated Ca2+ channels [8].
Since previous studies showed that mutations in ion 
channels are responsible for other paroxysmal dyskinetic 
phenotypes in the specific mouse models tottering, 
lethargic and moonwalker [6], it is tempting to speculate 
that paroxysmal motor symptoms can be generated by 
dysfunctions in either ion channels or presynaptic proteins 
regulating short-term synaptic plasticity, leading to 
network instability/hyperexcitability. In this landscape, the 
PRRT2 KO mouse emerges as an interesting experimental 
model to study the molecular basis of paroxysmal 
disorders and identify novel therapeutic targets to 
effectively cure these diseases.
Fabio Benfenati: Center for Synaptic Neuroscience and 
Technology, Istituto Italiano di Tecnologia, Largo Rosanna 
Benzi, Genova, Italy and Department of Experimental 
Medicine, University of Genova, Viale Benedetto, Benzi 
10, 16132 Genova, Italy
Correspondence to: Fabio Benfenati, email fabio.benfena-
ti@iit.it
Keywords: paroxysmal disorders, PRRT2 mutations, PRRT2 
knockout mouse, synaptic facilitation, network instability
Received: July 08, 2017
Published: July 24, 2017
REFERENCES
1. Valente P, et al. 2016; Cell Rep. 15: 117-131.
2. Liu YT, et al. Oncotarget. 2016; 7: 39184-39196. https:// 
doi.org/10.18632/oncotarget.9258.
3. Lee HY, et al. 2012; Cell Rep. 1: 2-12.
4. Ebrahimi-Fakhari D, et al. Brain. 2015; 138: 3476-3495.
5. Gardiner AR, et al. Brain. 2015; 138:3567-3580.
6. Michetti C, et al. Neurobiol Dis. 2017; 99: 66-83. 
7. Rossi P, et al. J Biol Chem. 2016; 291: 6111-6123.
8. Shen Y, et al. Proc Natl Acad Sci USA. 2015; 112: 2935-
2941.
Copyright: Michetti et al. This is an open-access article distribut-
ed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original author and 
source are credited.
